Subject: Big PZOO Update PSID Analyst Coverage

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
Big PZOO Update PSID Analyst Coverage
Hot Stock to WatchHot Stock to Watch

Company: Pazoo Inc. (Pink Sheets: PZOO)

End of Day:

Price: 0.0123

Change (%): + 0.00083 (7.24)

Volume: 9,848,377
PZOO Chart

Pazoo, Inc. Confirms Paying Off Note to Union Capital LLC, and Continues to Move Forward With Harris Lee, LLC

WHIPPANY, N.J., April 24, 2015 (GLOBE NEWSWIRE) - Pazoo, Inc. (OTC Pinks:PZOO) (German WKN#: A1J3DK), is pleased to announce that as of today, the company has completely repaid the total of its obligations on its Convertible Promissory Notes to Union Capital LLC. Pazoo announced on April 15th its intention to pay off Union Capital within ten days’ time. Pazoo made good today on its intentions. Pazoo’s next steps will be to pay off the Eastmore Capital Note within the next few weeks.

Pazoo felt it’s extremely important to let shareholders and the public know that it continues to meet its commitments, and assure the public that Pazoo is taking affirmative steps to prevent any conversions of these Notes into free trading shares of the company’s common stock. With several Notes now retired, Pazoo continues working towards building important relationships with more traditional financing sources.

Continue Reading

Top PerformerYesterday's Top Performer

PositiveID Corporation (OTCQB: PSID)

End of Day:

Price: 0.0198

Change (%): + 0.0017 (9.39)

Volume: 5,489,716
PSID Chart

Small Cap IR Issues Analyst Coverage of PositiveID Corporation

NEW YORK, April 24, 2015 /PRNewswire/ - Small Cap IR issues analyst report. PositiveID Corporation (OTCQB: PSID) is an emerging growth company and developer of biological detection and diagnostic systems for America’s homeland defense and the global healthcare market. The company specializes in developing microfluidic systems for the automated preparation of and performance of biological assays in order to be able to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need.

PositiveID develops biological detection and diagnostic systems, which includes its M-BAND and Firefly Dx systems, which use real-time polymerase chain reaction (PCR) chemistry. PCR amplifies a sample’s DNA and copies it billions of times. PCR is also used every day to diagnose diseases, identify bacteria and viruses. Real-time PCR is one of the most sensitive and specific bio-detection capabilities available today. Positive ID is primarily focused on its M-BAND airborne bio-threat detector, a development under contract with the U.S. Department of Homeland Security (“DHS”) Science & Technology directorate and it’s Firefly Dx System, which is designed to deliver molecular diagnostic results from a sample in less than 30 minutes using a portable, handheld system.

Continue Reading

Other Small Cap News

Company: Breathe eCig Corp. (OTCQB: BVAP)

Breathe eCig Corp. Fully Repays and Retires All Outstanding Convertible Debt Held by JMJ Financial with One Time Cash Payment

NEW YORK, Apr. 24, 2015 /PRNewswire/ -- Breathe eCig Corp. (OTCQB: BVAP) ("Breathe" or "the Company"), the electronic cigarette industry innovator and pioneer, has today announced that the Company has fully repaid and retired the convertible note ("the note") held by JMJ Financial ("JMJ") for the principal amount of $25,000 USD. On February 05, 2015, Breathe borrowed $25,000 USD from JMJ when the Company had accumulated bills relating to the process of completing the acquisition (most notably costs associated with auditing the financials). Including accrued interest and contractual buyout premiums, the note was officially retired for a one time cash payment of $27,500 USD. Therefore, there will be absolutely no share conversions owed to JMJ in conjunction with this note and the corresponding debt has been removed from the Company's balance sheet.

Continue Reading

Company: Latteno Food Corp. (Pink Sheets: LATF)

Latteno Food Corp. Creates New Subsidiary Latteno Science for R&D of Cannabinoids in Central America

BRIDGEPORT, CT--(Marketwired - Apr 24, 2015) - Latteno Food Corp. (OTC PINK: LATF) is pleased to announce the formation of a new subsidiary Latteno Science Corp. that will conduct research and development of cannabinoids in Central America. The most common natural plant cannabinoids (phytocannabinoids) are: THC, cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). CEO John Pinheiro comments: "We are very pleased to conduct research and development of cannabinoids with Latteno Science. Particular interest are the various strains of cannabinoids in Central America. It seems that the problem is that research facilities in the United States cannot duplicate the unique and complex strains of cannabinoids found in Central America. That is unfortunate because medical researchers from Central America are having surprisingly beneficial results in the treatment of various forms of cancer from cannabis from that region."

Continue Reading

Market News

By Scott Rutt: TheStreet

'Mad Money' Lightning Round: It's Time to Buy, Buy, Buy Kroger

NEW YORK (TheStreet) -- Here's what Jim Cramer had to say about some of the stocks during the Mad Money Lightning Round Thursday evening:

Noble Energy (NBL): "I think Noble is right right here. They're doing a good job."

Kroger (KR): "This is down 10% in a straight line. That tells me it's time to buy."

Cypress Semiconductor (CY): "I'm not backing away from Cypress."

Continue Reading

By Fred Imbert:

Early movers: BIIB, XRX, MSFT, AMZN, GOOG, SBUX & more

Check out which companies are making headlines before the bell:

Biogen's stock was under pressure ahead of the bell after the company's first-quarter sales of Tecfidera, an oral multiple sclerosis drug, came in at 824.90 million dollars, below consensus estimates, according to Reuters.

Xerox shares fell more than 3 percent after the company posted quarterly earnings and revenue that missed analysts' expectations. The company also cut its full-year forecast amid a strong U.S. dollar.

AstraZeneca shares fell more than 3 percent in premarket trading after the company reported that sales fell by 6 percent in the first quarter, citing a rising dollar and competition from Nexium generics, according to Reuters.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks